- Registered Pharmacy
- Secure Online Payments
- Discreet Next Day UK Delivery
- Over 100k Registered Patients
Wegovy is now available as a once-daily tablet – the same clinically proven semaglutide treatment as the Wegovy injection, but without the needles. The Wegovy pill is expected to launch in the UK around mid-July 2026 and we will be stocking it from day one.
If you have been putting off starting a semaglutide weight loss programme because of the injections, this is the option you have been waiting for. No injections at any point. No sharps disposal. No refrigeration. Just a tablet, taken first thing each morning with a small glass of water.
No injections – once-daily oral tablet
Same active ingredient as the Wegovy injection (semaglutide)
Average weight loss of approximately 16.6% in clinical trials
Stored at room temperature – no fridge needed
Does not affect the effectiveness of oral contraceptives
Expected UK launch: mid-July 2026
Dispatched within 1-2 working days once available
⏳ Not in stock yet – but you can secure your place now
The Wegovy pill is due to arrive with us around mid-July 2026, subject to MHRA approval. We are taking waiting list registrations and back-orders right now so that we can get your order out to you as quickly as possible once stock arrives.
Join the waiting list: Register your interest and we will contact you as soon as it is available. No payment required.
Place a back-order: Complete your consultation and pay now to secure your supply. Your order will be dispatched within 1-2 working days of us receiving stock – expected mid-July 2026.
We will not charge your card for a back-order until your item is ready to dispatch. You can cancel at any time before dispatch for a full refund.
The Wegovy pill is an oral tablet formulation of semaglutide – the same active ingredient that has already helped hundreds of thousands of people across the UK achieve meaningful, sustained weight loss through the Wegovy injection. It was developed by Novo Nordisk specifically for weight management in adults, and it works through exactly the same biological mechanism as the injection. The only difference is how it enters your body: a tablet you swallow once a day rather than a pen you inject once a week.
This matters a great deal for a significant group of people. Needle phobia affects somewhere between 20 and 25 percent of adults to a meaningful degree, and for many of them weekly self-injection simply is not a realistic long-term commitment – regardless of how much they want the clinical benefits. The Wegovy tablet removes that barrier completely. There are no injections at any stage of treatment, not when you start, not when the dose increases, not at any point.
Important – the Wegovy pill is not the same as Rybelsus. Rybelsus is an oral semaglutide tablet that is already licensed in the UK, but it is licensed only for the treatment of type 2 diabetes and comes in doses up to 14mg. The Wegovy tablet is a completely separate product, formulated specifically for weight management at a higher 25mg maintenance dose. They are not interchangeable.
The Wegovy tablet contains semaglutide as its active ingredient – the same molecule used in the Wegovy injection. Semaglutide mimics a naturally occurring hormone called GLP-1 (glucagon-like peptide-1), which plays a central role in regulating appetite and blood sugar.
Clinical trials for the tablet (the OASIS 4 study) showed average body weight reduction of approximately 16.6% over 64 weeks. It also reduces the risk of cardiovascular events and helps balance blood sugar levels in people with prediabetes. Like the injection, it does not affect the effectiveness of oral contraceptives – an important practical benefit that sets it apart from some other weight loss treatments.
Getting semaglutide to work as an oral tablet was a significant scientific challenge. Semaglutide is a peptide – a protein-based molecule – and the stomach’s acid and digestive enzymes would normally break it down before the body could absorb it. This is exactly why GLP-1 treatments have historically needed to be injected: the drug has to bypass digestion entirely.
The Wegovy tablet solves this using a technology called SNAC (Salcaprozate Sodium). Every tablet contains SNAC, which does two things at once: it shields the semaglutide from stomach acid and digestive enzymes, and it temporarily increases the permeability of the stomach lining in a localised way, allowing semaglutide to pass directly through the stomach wall and into the bloodstream.
This mechanism is the reason the taking instructions for Wegovy tablets are more specific than most oral medications. Every detail – empty stomach, plain water only, the 30-minute wait before eating or drinking anything else – has a direct impact on how much semaglutide your body actually absorbs. These are clinical requirements, not just suggestions.
The Wegovy tablet is suitable for adults who want to manage their weight, including weight loss and longer-term weight maintenance, alongside a reduced-calorie diet and regular exercise. Specifically:
Adults with a BMI of 30 or above (classified as obese)
Adults with a BMI of 27 or above (overweight) who also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, high cholesterol, or cardiovascular disease
These are the same eligibility criteria as the Wegovy injection. A full clinical assessment is required before any prescription is issued – this includes a review of your medical history, current medications, and any contraindications.
Who should not take the Wegovy pill: It is not suitable for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2, people with a history of pancreatitis or serious kidney problems, or anyone who is pregnant, planning pregnancy, or breastfeeding. It should not be taken alongside other semaglutide-containing medicines such as Ozempic or Rybelsus.
Starting Dose
Treatment starts at 1.5mg once daily for the first four weeks. This lower starting dose gives your body time to adjust and reduces the likelihood of gastrointestinal side effects in the early weeks.
Dose Escalation
After four weeks at 1.5mg, the dose increases to 4mg for the next four weeks, then 9mg, before reaching the maintenance dose of 25mg daily. Each step up happens only once the current dose is well tolerated. Your prescriber may recommend staying at a dose for longer than four weeks if you need more time to adjust. Every re-order with Dr Weightmans includes a clinical review to confirm the dose is appropriate for your current progress.
Dose Schedule at a Glance
Month 1 – 1.5mg – Starting dose, allows the body to adjust
Month 2 – 4mg – First dose increase if well tolerated
Month 3 – 9mg – Continued escalation
Month 4+ – 25mg – Maximum maintenance dose
Because the tablet relies on the SNAC absorption mechanism, the way you take it has a direct effect on how much semaglutide actually reaches your bloodstream. These are not optional guidelines – they are clinical requirements.
Take it first thing in the morning, on a completely empty stomach.
Swallow with no more than 120ml (about half a glass) of plain water only – not coffee, juice, milk, or any other drink.
Swallow the tablet whole – do not crush, cut, chew, or dissolve it.
Wait at least 30 minutes before eating food, drinking anything other than plain water, or taking any other oral medications.
Take it at the same time each morning to build a reliable routine.
If you miss a dose, skip it and resume your normal schedule the following morning – never take two doses to make up for a missed one.
Keep it in the original bottle at room temperature – do not transfer to another container.
Practical tip: Keep the bottle and a small glass of plain water on your bedside table so you can take it the moment you wake up, before breakfast or coffee becomes a temptation.
Coming Soon
The Wegovy tablet shares broadly the same side effect profile as the Wegovy injection, since both deliver semaglutide through the same biological mechanism. The most commonly reported effects are gastrointestinal in nature and tend to be most noticeable during the early weeks of treatment or following a dose increase. They generally improve as the body adjusts to each new dose.
Common side effects include nausea, vomiting, diarrhoea, constipation, stomach pain, bloating, indigestion, headache, fatigue, and dizziness. The gradual dose escalation schedule is specifically designed to minimise these – moving up doses too quickly is the main reason gastrointestinal side effects become difficult to manage.
Less common but more serious side effects include pancreatitis (severe or persistent stomach pain, with or without vomiting), gallbladder problems (strong pain after meals, or yellowing of the skin or eyes), increased resting heart rate, and kidney problems. Anyone experiencing severe or persistent abdominal pain should stop the medication and contact their prescriber or seek medical attention promptly.
Allergic reactions are rare but can occur. Signs include difficulty breathing or swallowing, or swelling of the face, lips, or tongue. If you experience any of these, stop the medication and seek urgent medical help.
Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use if you have a history of pancreatitis or serious gastrointestinal disease.
Do not use alongside other semaglutide-containing medicines such as Ozempic or Rybelsus.
Do not use if you are hypersensitive to semaglutide or any of the other ingredients in the tablet.
Not recommended during pregnancy, when planning a pregnancy, or while breastfeeding. Avoid for at least two months before attempting to conceive.
Semaglutide slows stomach emptying, which can affect how other oral medications are absorbed. Always inform your prescriber about all other medications you are taking.
Recommended for adults aged 18 and over only.
We aim to provide a fast, reliable, and discreet delivery service across the UK.
Special Delivery Guaranteed – £11.99
• Guaranteed Delivery before 1pm on the next working day via Royal Mail Special Delivery
• Same-day dispatch for orders placed before 2pm on weekdays
• Requires a signature upon delivery
Express Tracked – £4.99
• Delivery within 1–2 working days via Royal Mail Tracked 24
• Same-day dispatch for orders placed before 2pm on weekdays
Orders placed before 2pm on weekdays are usually dispatched the same day, subject to stock availability and clinical approval (if applicable).
Orders placed after 2pm or during weekends/bank holidays will be processed the next working day.
Where additional information is required after checkout, please provide this promptly to avoid any delays in dispatching your order.
Your privacy is important to us.
All orders are shipped in plain, unbranded packaging, with no reference to the contents or our pharmacy name.
We currently do not offer international shipping. Our services are limited to customers within the UK.
The Wegovy pill contains exactly the same active ingredient – semaglutide – as the Wegovy injection pen. It works through the same mechanism, targeting the same GLP-1 receptors to reduce appetite and slow stomach emptying. The difference is purely in how you take it: a tablet once a day rather than an injection once a week. The clinical trial data shows results that are closely comparable between the two formulations.
Yes, based on the available evidence. The OASIS 4 clinical trial showed approximately 16.6% average body weight reduction over 64 weeks with the oral tablet. For comparison, the Wegovy injection trials showed around 15% over 68 weeks. Once semaglutide is absorbed into the bloodstream, it works identically regardless of how it got there. The SNAC technology in the tablet is specifically designed to achieve reliable absorption.
We expect MHRA approval and UK availability around mid-July 2026. The Wegovy tablet has already launched in the United States, where it received FDA approval in December 2025 and became available from January 2026. Dr Weightmans intends to stock it as soon as it is available in the UK. You can join our waiting list or place a back-order now to secure your supply.
No. Rybelsus is also an oral semaglutide tablet and is already available in the UK, but it is licensed only for the treatment of type 2 diabetes. It comes in doses up to 14mg. The Wegovy tablet is a completely separate product, formulated specifically for weight management at a maintenance dose of 25mg. The two medications are not interchangeable.
Adults with a BMI of 30 or above, or adults with a BMI of 27 or above who also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. A full online clinical consultation is required before any prescription can be issued. This is the same eligibility criteria as the Wegovy injection.
This is something to discuss with your prescriber at your next clinical review. The two formulations contain the same active ingredient, and patients who are progressing well on the injection but would prefer a needle-free option may be able to switch. Your prescriber will assess the most appropriate approach based on your current dose and progress.
No – this is one of the practical advantages over the injection. The Wegovy tablet is stored at room temperature in its original bottle. No cold-chain storage is needed, which makes travel and daily routine considerably simpler.
Taking the Wegovy tablet with anything other than plain water, or eating before the 30-minute window has passed, significantly reduces how much semaglutide your body absorbs through the stomach lining. The SNAC mechanism depends on the stomach being empty and undiluted. Reducing absorption means the medication is less effective – so following the taking instructions carefully is directly tied to how well the treatment works for you.
The medication begins acting from the first dose, but noticeable changes to appetite and eating habits typically develop over the first few weeks. Meaningful weight loss tends to build progressively during the dose escalation phase, with the most significant results seen once you reach and maintain the 25mg dose. As with all GLP-1 treatments, the medication works while you take it – stopping treatment will likely result in some weight returning over time.
Kindly visit the GPhC website here to find information on how to verify the registration status of the pharmacy and the superintendent pharmacist.
Copyright © 2026 Fishmoor Healthcare LTD, DrWeightmans is a Trademark, All rights reserved. Company Registration No: 13368234| VAT Registration No: GB409334308
